Brainstem Biopsy and Targeted Therapies in Pediatric Brain Tumors
Author Information
Author(s): Sheikh Shehryar R., Recinos Violette M. R., Thompson Eric M., Mangum Ross, Wright-Nadkarni Mariah, Gampel Bradley, Patel Neha J.
Primary Institution: Cleveland Clinic
Hypothesis
The necessity and safety of brainstem biopsies in diagnosing and managing pediatric diffuse midline gliomas (DMG) and diffuse intrinsic pontine gliomas (DIPG) is evaluated.
Conclusion
Contemporary pediatric brainstem biopsies are safe and can provide valuable molecular profiles that may guide targeted therapies.
Supporting Evidence
- Biopsies have a diagnostic success rate of over 96%.
- Permanent complications from biopsies are rare, with rates not exceeding 2%.
- Biopsies can provide molecular profiles that may guide targeted therapies.
- Studies show that biopsies can help design better clinical trials.
- Liquid biopsy techniques are being explored to enhance diagnostic precision.
Takeaway
Doctors can safely take small samples from the brainstem to help figure out the best treatment for kids with certain brain tumors.
Methodology
This review analyzes multiple studies and meta-analyses regarding the safety and utility of brainstem biopsies in pediatric patients with DMG/DIPG.
Potential Biases
Potential bias exists due to the reliance on retrospective data and the variability in practice among different centers.
Limitations
The evidence is primarily derived from retrospective case series, which may not fully represent the current standard of care.
Participant Demographics
Pediatric patients with suspected diffuse midline gliomas, primarily under 21 years of age.
Statistical Information
Confidence Interval
95% CI 0.5-2.2 for permanent complications
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website